Document Type

Paper

Publication Date

3-17-2014

Abstract

CXCR4 is a co-receptor on the surface of immune cells that has been proven to facilitate the entry of HIV into the cells. Within the last 15 years the CXCR4 and CCR5 coreceptors have influenced new therapeutic approaches to the treatment of HIV via fusion inhibitor drugs that target these receptors. Our aim is to develop new antagonists for the CXCR4 coreceptor. Specifically, the goal was the synthesis of Propyl Cross-Bridged, linked analogues of the known CXCR4 antagonist AMD-3100.

Comments

Source: 2014 Spring National Meeting of the American Chemical Society, Dallas, TX

Share

COinS